1 of 1
Story summary
- The epilepsy drug sultiame may treat obstructive sleep apnea by reducing breathing interruptions and improving nocturnal oxygen levels at higher doses.
- The trial involved 298 adults across four European countries.
- The findings, published in The Lancet, indicate sultiame is not yet approved for OSA and requires further studies.
- If confirmed, sultiame could offer a simpler alternative to CPAP machines and transform sleep apnea treatment.
